Abstract
Identification of Anderson-Fabry disease (AFD) in cardiac patients has been restricted so far to patients with left ventricular hypertrophy. Coronary microvascular dysfunction has been described in AFD with and without cardiac hypertrophy and may represent the only manifestation in AFD patients, offering a possible earlier diagnosis. We studied the prevalence of AFD in 663 patients with chest pain with normal or non-obstructive coronary arteries. The overall prevalence of AFD in this cohort was only 0.15% (1/663). AFD is not a frequent cause of chest pain without obstructive coronary artery disease and screening efforts should not be conducted in this patient population.
This is a preview of subscription content, log in via an institution to check access.
References
Ortiz, A., Germain, D. P., Desnick, R. J., Politei, J., Mauer, M., Burlina, A., et al. (2018). Fabry disease revisited: management and treatment recommendations for adult patients. Molecular Genetics and Metabolism, 123(4), 416–427.
Reisin, R., Perrin, A., & García-Pavía, P. (2017). Time delays in the diagnosis and treatment of Fabry disease. International Journal of Clinical Practice, 71, e12914.
López-Sainz, Á., Climent, V., Ripoll-Vera, T., Espinosa, M. A., Barriales-Villa, R., Navarro, M., et al. (2019). Negative screening of Fabry disease in patients with conduction disorders requiring a pacemaker. Orphanet Journal of Rare Diseases, 14(1), 170.
Tomberli, B., Cecchi, F., Sciagrà, R., Berti, V., Lisi, F., Torricelli, F., et al. (2013). Coronary microvascular dysfunction is an early feature of cardiac involvement in patients with Anderson-Fabry disease. European Journal of Heart Failure, 15(12), 1363–1373.
Kitani, Y., Nakagawa, N., Sakamoto, N., Takeuchi, T., Takahashi, F., Momosaki, K., et al. (2019). Unexpectedly high prevalence of coronary spastic angina in patients with Anderson-Fabry Disease. Circulation Journal, 83(2), 481–484.
Funding
This work was partially supported by grants from Shire-Takeda (Investigator Initiated Research Grant 2018-IIR-ESP-001305) and by the Instituto de Salud Carlos III (PI17/01941). Funders played no role in the design, collection, analysis, or interpretation of the data or in the decision to submit the manuscript for publication.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
VC reports consulting fees and research funding from Sanofi-Genzyme, Takeda, and Amicus. PGP reports consulting fees and research funding to his institution from Sanofi-Genzyme and Takeda. Other authors have no conflict of interest relevant to this work to declare.
Ethical Approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed Consent
Informed consent was obtained from all individual participants included in the study.
Additional information
Editor-in-Chief Enrique Lara-Pezzi oversaw the review of this article
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Hernández-Hernández, A., Diez-López, C., Azevedo, O. et al. Screening of Fabry Disease in Patients with Chest Pain Without Obstructive Coronary Artery Disease. J. of Cardiovasc. Trans. Res. 14, 948–950 (2021). https://doi.org/10.1007/s12265-020-10097-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12265-020-10097-2